of Maxwell (18) and Feynman (19) , devices with nanoscale dimensions may actually approach the limit of the second law of thermodynamics, be they mechanically (20) or electrically (21) driven. Our results point the way for the creation of such a mechanical "ratchet and pawl" device, although the asymmetric periodic profile in our experiment here may not be sufficiently strong at room temperature to ensure the necessary conditions for a completely unidirectional rotation of the molecular rotor (17) . The rotor (or the cavity) has to be reengineered to optimize the supramolecular ratchet-bushing interaction. In this case, to drive the rotor unidirectionally by thermal means, an additional input is required to increase the rotor potential energy over the ratchet potential barrier at pseudorandom time intervals (14, 17) . For example, a tunnel current input on the bearing will inelastically heat the rotor (22) , thus providing a method to rectify thermal noise.
Our results open the way to fabricate, spatially define, and test recent proposals involving mechanical devices fabricated in molecular structures. They raise interesting questions concerning the fundamentals of mechanics in molecular and supramolecular systems, including the role of thermal noise and the design of molecular devices.
discussions, and A. K. Lay for help in the chemical synthesis. Supported by the European Union ESPRIT project "Nanowires," which is partially funded by the Swiss Federal Office for Education and Science. Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the adenosine triphosphate-binding site of the human cyclin-dependent kinase 2 (CDK2). By iterating chemical library synthesis and biological screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified. The structural basis for the binding affinity and selectivity was determined by analysis of a three-dimensional crystal structure of a CDK2-inhibitor complex. The cellular effects of these compounds were characterized in mammalian cells and yeast. In the latter case the effects were characterized on a genome-wide scale by monitoring changes in messenger RNA levels in treated cells with high-density oligonucleotide probe arrays. Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may lead to the development of new therapeutics.
Biomedical research has been aided tremendously by three developments: (i) the ability to generate small molecule libraries using combinatorial chemistry methods coupled with high-throughput screening, (ii) the enormous increase in the number of newly identified gene sequences from a host of different organisms, and (iii) the use of structural methods for the detailed characterization of ligand-protein interaction sites that can be exploited for ligand design. Here we applied these methods to the synthesis and characterization of potent, selective inhibitors of protein kinases involved in cell cycle control. The central role that cyclin-dependent kinases (CDKs) play in the timing of cell division and the high incidence of genetic alteration of CDKs or deregulation of CDK inhibitors in a number of cancers make CDKs a promising target for the design of selective inhibitors. Our approach to inhibiting CDKs has been to block the adenosine triphosphate (ATP)-binding site with compounds derived from combinatorial libraries of 2,6,9-trisubstituted purines. This strategy was motivated by the binding mode of the purine olomoucine, which exhibits good selectivity but only moderate inhibition [IC 50 (50% kinase inhibition) ϭ 7 M] of a subset of the CDK family of protein kinases (1) . The orientation of the purine ring of olomoucine within the ATP-binding site of CDK2 is rotated almost 160°relative to that of the adenosine ring of ATP. Thus, it seemed that the introduction of new substituents at the 2, 6, and 9 positions of the purine ring, rather than substituents appended to the ribose, as is normally done, might lead to enhanced binding affinity and selectivity. A combinatorial approach to modifying the purine scaffold could be valuable in the search for potent and selective inhibitors of various cellular processes because of the ubiquitous occurrence of enzymes that use purines, including the estimated 2000 kinases encoded in the human genome.
To examine the effects of a range of diverse substituents on the purine ring, we synthesized combinatorial libraries in which the 2, 6, and 9 positions could be varied starting with a 2-fluoro-6-chloropurine framework (Fig. 1A) (2, 3) . Substitution chemistry was used to install amines at the 2 and 6 positions, and a Mitsunobu reaction (4, 5) was used to alkylate the N9 position of the purine core. The substitution chemistry allows introduction of primary and secondary amines bearing a wide range of functional groups, whereas the Mitsunobu reaction tolerates primary and secondary alcohols lacking additional acidic hydrogens. Newly appended groups can be modified combinatorially in subsequent steps with a variety of chemistries including acylation, reductive amination, and Suzuki coupling reactions (6 ) . During library synthesis, one position is held invariant to allow attachment to the solid support. Libraries are synthesized in a spatially separated format with either a pin apparatus (7) or polystyrene resin and screened for kinase inhibitors with a 96-well, solutionphase phosphorylation assay.
Several purine libraries in which the 2, 6, and 9 substituents were varied separately were iteratively synthesized and screened. We identified aA number of 3-and 4-substituted benzylamine and aniline substituents that lead to significant improvements in CDK2 binding when introduced at the 6 position of the purine ring. For example, replacement of the benzylamino group of olomoucine at the C6 position with 3-chloroaniline resulted in a 10-fold increase in the IC 50 . Although a variety of hydroxyalkylamino, dihydroxyalkylamino, and cycloalkylamino substituents at the 2 position resulted in moderate improvements in binding affinity, greater increases were achieved with amino alcohols derived from alanine, valine, and isoleucine. For example the R-isopropyl side chain of valinol resulted in a 6.5-fold increase relative to the hydroxyethyl substituent of olomoucine. In contrast to many protein kinases that can accommodate larger substituents at the N9 of the purine ring, CDK2 binding was strongest for those purines bearing small alkyl or hydroxyalkyl substituents. Those substituents that resulted in the most potent CDK2 inhibition were combined in secondgeneration libraries by solution-phase chemistry. The IC 50 data for these series of compounds indicate that the inhibitory effects of these substituents are approximately additive.
Currently, our most potent inhibitor, 2-(1R-isopropyl-2-hydroxyethylamino)-6-(3-chloro-4-carboxyanilino)-9-isopropylpurine (purvalanol B, Fig. 1D ), has an IC 50 against the complex of CDK2-cyclin A of 6 nM, which corresponds to a 1000-fold increase over olomoucine and a 30-fold increase over flavopiridol (Fig. 1B) , one of the most potent and selective CDK2 inhibitors known and currently in human clinical trials (8) . Purvalanol B shows a high degree of selectivity: among the 22 human purified kinases tested (1, 9) , only a subset of the CDKs (cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E, CDK5-p35) were significantly inhibited (Table 1) . Several close analogs of purvalanol B were also potent inhibitors of cdc2 and CDK2, including the more membrane permeable analog purvalanol A and compound 52 [(2-(2-hydroxyethylamino)-6-(3-chloroanilino)-9-isopropylpurine, IC 50 ϭ 340 nM against cdc2-cyclin B] (Fig. 1E, Table 2 ). We also assessed the selectivity of purvalanol A, compound 52, and a N6-methylated version of compound 52 (52Me) against four yeast CDKs (10) (Cdc28p, Kin28p, Pho85p, and Srb10p) and the related kinase Cak1p using kinase assays performed in immunoprecipitates (Table 2 ) (11) . Of the yeast kinases tested, only the cell cycle-regulating kinase Cdc28p and the highly homologous Pho85p kinase (50% identity to Cdc28p), which is involved in phosphate metabolism, were inhibited by purvalanol A and 52. Compound 52Me did not inhibit any of the CDKs tested.
To explore the structural basis for the selectivity and affinity of these inhibitors we Protein kinase C ␣ Ͼ 10,000 Ͼ100,000 Protein kinase C ␤1 Ͼ10,000 Ͼ100,000 Protein kinase C ␤2 Ͼ10,000 Ͼ100,000 Protein kinase C ␥ Ͼ 10,000 Ͼ100,000 Protein kinase C ␦ Ͼ 100,000 Ͼ100,000 Protein kinase C Ͼ 100,000 Ͼ100,000 Protein kinase C Ͼ 100,000 Ͼ100,000 Protein kinase C Ͼ 100,000 Ͼ100,000 cAMP-dependent protein kinase 9,000 3,800 determined the crystal structure of the human CDK2-purvalanol B complex to 2.05 Å resolution (12) (Fig. 2) . The electron density map shows that binding of purvalanol B to the CDK2 crystals is well ordered except for the 3-chloroanilino group, which appears to be bound in two alternative conformations (Fig. 2) . Purvalanol B fits snugly into the ATP-binding site, as is evident by the 86% complementarity between the surface area buried by the inhibitor (364 Å 2 ) compared with the available binding surface in the active site of the protein (423 Å 2 ). The overall geometry of purvalanol B bound to CDK2 resembles that of the related adenine-substituted inhibitors in the CDK2-olomoucine and CDK2-roscovitine complexes, with the purine ring and its C2, N6, and N9 substituents occupying similar binding pockets. The purine ring makes mostly hydrophobic and van der Waals contacts with CDK2 residues. A pair of conserved H bonds are present between the N7 imidazole nitrogen and the backbone NH of Leu
83
, and between the N6 amino group and the backbone carbonyl of Leu 83 ; this latter interaction likely accounts for the greatly reduced inhibitory activity resulting from methylation of N6 in compound 52Me. Furthermore, all three 2,6,9-trisubstituted adenines form a H bond between the acidic C8 atom of the purine ring and the carbonyl oxygen of Glu 81 , an infrequently observed interaction in the crystal structures of nucleic acids and proteins (13) .
The C2 side chain of purvalanol B is bound in the ATP ribose-binding pocket ( Fig. 2A, structure 3) , with the R-isopropyl group closely packed against backbone atoms of the glycine-rich loop and the hydroxyl group making a H bond with the backbone carbonyl of Gln 131 . The R-isopropyl side chain of purvalanol B leads to a significant repositioning of the C2 substituent relative to the R-ethyl substituent of roscovitine ( Fig.  2A, structure 1 In the CDK2-flavopiridol complex, this region is occupied by the N-methylpiperidinyl ring of the inhibitor ( Fig. 2A ., structure 2), suggesting that further increases in affinity of purvalanol B may result from appending substituents at the C2 position that interact with this site. The 3-chloroanilino group at N6 of purvalanol B points toward the outside of the ATP-binding pocket, a region not occupied in the CDK2-ATP complex. Interactions in this region are likely responsible for the increased affinity and selectivity of the inhibitors compared with ATP and are evident in the CDK2 complexes of flavopiridol, olomoucine, and roscovitine as well. In the CDK2-purvalanol B complex, the 3-chloroanilino group of the inhibitor is packed tightly against the side chains of Ile 10 and Phe 82 . Further stabilization of the binding of the 3-chloroanilino group comes from a polar interaction between the Cl and the side chain of Asp 86 , which appears to be present in about twothirds of the molecules in the CDK2-purvalanol B crystals. In the other conformation the phenyl ring of the 3-chloroanilino group is flipped ϳ160°, suggesting a partially protonated state of Asp 86 . In addition to improved packing interactions, the increased binding affinity of purvalanol B relative to olomoucine may result from steric constraints imposed by the purine and chlorinated aniline ring systems that limit the number of conformations of the inhibitor. Numerous substituents at the 4 position of the aniline ring were tolerated, consistent with the solvent accessibility of this site, which makes this position an obvious candidate for altering both the solubility and membrane permeability. Finally, the N9 isopropyl group of purvalanol B packs in a small hydrophobic pocket formed by the side chains of Val 18 , Ala 31 , Phe 80 , Leu 134 , and Ala 144 , consistent with the narrow range of substituents that can be tolerated at this position.
To determine the cellular effects of these CDK-directed cell cycle inhibitors, we tested purvalanol A on the NCI panel of 60 human tumor cell lines (leukemia, non-small cell lung cancer, colon cancer, renal cancer, prostate cancer, and breast cancer). Although the average GI 50 (50% growth inhibition) is 2 M, two cell lines out of the 60 showed an ϳ20-fold increase in sensitivity to purvalanol A: the KM12 colon cancer cell line with a GI 50 of 76 nM and the NCI-H522 non-small cell lung cancer cell line with a GI 50 of 347 nM. Fluorescence-activated cell sorting (FACS) analysis of human lung fibro- 
blast cells treated with a structural analog of purvalanol A, 2-(bis-(hydroxylethyl) amino)-6-(4-methoxybenzylamino)-9-isopropylpurine, exhibited both G 1 -S and G 2 -M inhibitory activity at high concentrations and predominant G 1 -S inhibition at lower concentrations (14) . Significant inhibition was also observed in Saccharomyces cerevisiae, where compound 52 inhibited growth in a drug-sensitized yeast strain (15) with a GI 50 of 30 M. In contrast, the closely related compound 52Me proved to be a significantly weaker inhibitor of yeast growth (GI 50 ϭ 200 M) (16) . In addition to measuring the inhibitory effects of these purine derivatives in kinase assays and assays of cell growth, their effects on the mRNA levels of nearly all yeast genes were determined with high-density oligonucleotide expression arrays (17, 18) . These arrays (19, 20) make it possible to measure quantitatively and in parallel mRNA levels for a very large number of genes after chemical, environmental, or genetic perturbation. Because purvalanol analogs inhibit both human and S. cerevisiae CDKs, transcript profiles were obtained in yeast, where they can be measured on a genome-wide scale. Compounds 52 and flavopiridol were profiled to examine the effects of two structurally different Cdc28p active site inhibitors on gene expression. Compound 52Me was profiled as a control to determine which transcriptional changes result from treatment with a structurally similar compound with greatly diminished CDK activity. Yeast cultures were grown to late logarithmic phase (15) , treated with 25 M concentrations of the inhibitors for 2 hours, after which cellular polyadenylated mRNA was isolated and converted to biotin-labeled complementary RNA (cRNA) (17, 18 ). The labeled cRNA was then hybridized to a set of four arrays containing more than 260,000 25-nucleotide oligomers (20) .
Out of more than 6200 genes monitored, 194 (3% of transcripts), 2 (0.03% of transcripts), and 132 (2% of transcripts) showed a greater than twofold change in transcript level when treated with 52, 52Me, or flavopiridol, respectively (21) . Consistent with the diminished activity of 52Me both in vivo and in vitro, far fewer transcripts were affected by compound 52Me than by the CDK inhibitors. Of the 63 transcripts that changed in response to both CDK inhibitors 52 and flavopiridol, only nine were down-regulated, five of which (CLB1, CLB2, HTA2, HTB2, EGT2) were associated with cell cycle progression (Fig.  3A) . The transcript encoded by CLB1 (G2 cyclin, implicated in the transition into mitosis) showed a significant decrease, consistent with inhibition of the Cdc28p-Clb1/2p kinase, which is involved in a positive feedback loop driving CLB1/2 transcription (22). Similarly, CDK activity has been implicated in transcriptional regulation of histone genes including HTA2 and HTB2 (23) , and EGT2, a gene involved in the timing of cell separation after cytokinesis.
Another set of genes that are clearly affected by both 52 and flavopiridol (but not by 52Me) are ones involved in phosphate metabolism, consistent with the observed in vitro inhibition of Pho85p (Fig. 3B) . Intracellular phosphate levels in yeast are monitored by a system that relies on the Pho85p kinase complex to modulate the activity of a transcription factor or factors that regulate a va- (PHO8, vacuolar alkaline phosphatase); YBR296c (homologous to a phosphate-repressible permease). (C) Transcripts that change for cdc28-4, cdc28-4 and 52, cdc28-4 and flavopiridol, and 52: YBR147W (unknown, has 7 potential transmembrane domains); YOL155C (unknown, similar to glucan 1,4-␣-glucosidase); YJR127C (ZMS1, similar to Arp1p, an Nacetyltransferase); YKL109W (HAP4, transcriptional activator protein involved in activation of CCAAT box-containing genes); YBL015w (ACH1, acetyl-coenzyme A hydrolase); YPR160W (GPH1, glycogen phosphorylase); YAL039C (CYC3, cytochrome c heme lyase); YML116W (ATR1, member of major facilitator superfamily); YCL009C (ILV6, acetolactate synthase regulatory subunit); YDR281C (unknown); YGL121C (unknown); YKL071w (unknown, similar to bacterial protein csgA); YLR311C (unknown); YER037w (unknown); YOR248W (unknown). *Names marked by an asterisk indicate open reading frames for which at least one hybridization of the set indicated a slightly less than twofold change in abundance.
riety of genes, including a secreted acid phosphatase (Pho5p) (24) , genes involved in the stress response (the heat shock protein HSP12 and ubiquitin UBI4), and genes involved in glycogen metabolism. Proteins whose transcript levels were observed to increase for 52 or flavopiridol that are consistent with inhibition of the Pho85p kinase include Pho80p (whose transcription is known to be repressed by active Pho85), Pho81p (an endogenous Pho85-Pho80 inhibitor), Pho84p (a phosphate permease), Pho5p, CTT1p, HSP12p, and UBI4 (25) . Notably absent from this list is glycogen synthase (GSY2) (26) , despite the large number of other glycogen metabolism mRNAs that change. Dissecting the transcriptional consequences of Pho85 inhibition (27) is additionally complicated because Pho85p associates with a large number of other cyclins (for example, Pcl1p-Pcl8p) (28) to yield complexes of unknown function that may also be subject to inhibition.
Compound 52 and flavopiridol also affect the transcript levels of many genes involved in cellular metabolism. For example, genes involved in glycolysis (PFK26 and YAL061W, an alcohol dehydrogenase), the citric acid cycle (ALD4), glycogen metabolism (PGM2 and YPR184W, a putative debranching enzyme), gluconeogenesis (PCK1), and a probable sugar transporter (HXT5), were induced. Other changes in transcript levels that were in common to both compounds and are likely to be associated with drug exposure include up-regulation of a number of genes encoding members of the ATP-binding cassette superfamily and other transport proteins (PDR10, PDR15), cell wall glycoproteins (YER150w), and cell wall proteins implicated in increased drug resistance (GSC2) (29) ; genes involved in vacuole endocytosis and regulation (YPT53, PMC1); and several heat shock genes (HSP26, HSP30, HSP82, HSP104, SSE2). Additional genes with changes in common to both compounds include a GTP-and ATP-binding protein (YDL223c) that putatively binds microtubules, l-myo-inositol-1-phosphate synthase (INO1), and 40 genes of unknown function. Very few of the 52 and flavopiridol-inducible genes were significantly induced by 52Me, suggesting that many of the drug-sensing mechanisms may respond to signals associated with the function rather than the structure of the drug.
Although Cdc28p is the intended target of both 52 and flavopiridol, more than half of the mRNA changes that result from exposure to the two compounds are distinct. For example, of the ϳ50 genes whose transcript levels were decreased at least threefold in response to 52, 14 were ribosomal proteins (including RPL4A, RPL26B, RPS24A). In contrast, no ribosomal protein transcript levels decreased more than threefold after treatment with flavopiridol. These results suggest that the two compounds may inhibit Cdc28p function (10) or affect pathways involving Cdc28p kinase activity to different degrees. Alternatively, the differential effects of the two compounds may result from different intracellular concentrations or from their effects on other cellular targets not specifically examined in vitro. Given the relatively large number of transcripts that are differentially affected by these two CDK inhibitors, we examined the transcriptional consequences of a genetic mutation in the Cdc28p kinase. Because CDC28 is an essential gene, the transcript profile of two cdc28 temperature-sensitive alleles [cdc28-4 and cdc28-13 (30) ] and their isogenic wild-type strains were measured under permissive growth conditions (25°C) in which the degree of growth inhibition approximates that observed at the concentrations used in the inhibitor profile experiments (31) . The mutation leading to a reduction in Cdc28p kinase activity in the cdc28-4 mutant under permissive growth conditions (32) might be expected to simulate the effects of chemical inhibition.
Approximately 100 mRNAs in the cdc28-4 strain exhibited more than twofold inductions over the wild type (Fig. 3C ). Only two of the cell cycle-associated genes (histones HTA1 and HTA2) that changed in response to flavopiridol or 52 were affected in this mutant (33) . Instead, as with flavopiridol and 52, a number of metabolic genes involved in glycogen synthesis, the citric acid cycle, gluconeogenesis, and the glyoxylate cycle were induced (Fig. 3C) . Consistent with these changes is the induction of the HAP4 transcription factor, which has been implicated in the regulation of many respiration genes (34) . Another class of transcripts induced in cdc28-4 were for genes involved in stress signaling (35) , as well as heat shock elements, stress response elements, and members of the major facilitator superfamily. Other transcripts that were also affected by CDC28 mutation and in the small-molecule experiments include virtually all of the transcription factors and many of the metabolic, biosynthetic, and stress response genes as well as a set of unknown genes, some of which may be linked to cell cycle regulation. However, there were also a number of genes in these functional categories that showed significant changes only for the cdc28-4 mutant, including a protein with transmembrane domains (YOL155C), metabolic genes (ACH1), and a variety of proteins of unknown function. The transcriptional responses to this single point mutation in CDC28 can be interpreted as cellular responses that tend to mitigate the effects of this alteration. Complete inactivation of Cdc28p kinase activity, rather than the partial inhibition at 25°C, may result in more cell cycle-related transcript changes. However, a host of additional changes associated with cell cycle arrest and secondary consequences of heat shock (required to induce arrest) are likely to appear as well, and these changes may complicate interpretation of the profile results.
Our current experimental design does not allow us to definitively identify the primary target or targets of inhibition by flavopiridol or 52. However, most of the genes that were commonly down-regulated by the two compounds are known to be involved in cell cycle progression and are affected in a way that is consistent with inhibition of Cdc28p activity. The transcript profiles also show distinct and reproducible differences in the effects of the two compounds despite their similar in vitro activity. Profiles of this sort may prove useful in evaluating the selectivity of drug candidates and in identifying proteins whose inhibition might specifically potentiate the effects of a primary drug. The lack of correspondence in the changes of mRNA transcript levels resulting from chemical and genetic inactivation underscores the intrinsic differences in these methods for modulating biological function.
Given the large number of purine-dependent cellular processes, purine libraries may serve as a rich source of inhibitors for many different protein targets. Indeed, purine analogs have been identified that selectively inhibit JNK kinase and glycogen synthase kinase (36, 37) . By screening these libraries for their effects in whole-cell assays, it should be possible to search for compounds with a wide variety of activities (38) . Both gene expression profiles and differential gene expression libraries should facilitate identification and characterization of targets (39) . These and other approaches to generating selective inhibitors of different cellular processes should complement genetic methods in the study of cellular function.
Synthesis of Macroporous Minerals with Highly Ordered Three-Dimensional Arrays of Spheroidal Voids
Brian T. Holland, Christopher F. Blanford, Andreas Stein* Titania, zirconia, and alumina samples with periodic three-dimensional arrays of macropores were synthesized from the corresponding metal alkoxides, using latex spheres as templates. In a fast, single-step reaction, the monomeric alkoxide precursors permeate the array of bulk polystyrene spheres and condense in air at room temperature. Close packed, open-pore structures with 320-to 360-nanometer voids are obtained after calcination of the organic component at 575°C. The examples presented demonstrate the compositional diversity possible with this technique. The resulting highly structured ceramics could have applications in areas ranging from quantum electronics to photocatalysis to battery materials.
The use of organic templates to control the structure of inorganic solids has proven very successful for designing porous materials with pore sizes ranging from angstroms to micrometers. In the case of microporous silicates and aluminosilicates, the organic additives are molecular and lead to zeolitic structures. Larger mesopores are obtained by using surfactant arrays or emulsion droplets as templates (1) (2) (3) (4) . Recent reports illustrate that techniques using latex spheres or block-copolymers can be used to create silica structures with pore sizes ranging from 5 nm to 1 m (5-8). Porous solids have made a great impact in applications including catalysis, sorption, and separations (9) . Advanced optoelectronics applications that would benefit from a facile method of producing large quantities of porous materials in various compositions with high degrees of three-dimensional (3D) order have been proposed (10) . For example, quantum electronics and optical communications require single-mode microcavities constructed from dielectric materials with adjustable composition and multidimensional periodicity (11) . So far, the fabrication of such structures with periodicity in three dimensions and feature sizes below 1 m has remained an experimental challenge (12) . Catalysis and large-molecule separation processes would also benefit from more uniform porous supports that provide optimal flow and improved efficiencies (13, 14 ) .
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